The US government has provided almost $24 million in funding to Locus Biosciences to support a mid-stage trial of LBP-EC01, a CRISPR-engineered bacteriophage therapy in development for resistant ...
© 2026 Forbes Media LLC. All Rights Reserved.
© 2026 Forbes Media LLC. All Rights Reserved.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results